MedTrace Logo

Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis

NCT06031012 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2026-03-12

No results posted yet for this study

Summary

The goal of this study is to compare glutamine combined with thalidomide with glutamine in preventing radiation-induced oral mucositis. The aim of this study is to answer whether glutamine plus thalidomide could improve the median incidence time of grade 2 oral mucositis. Participants would be randomly divided into the two groups above mentioned.

Conditions

  • Mucositis Oral

Interventions

DRUG

glutamine combined with thalidomide

Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.

DRUG

glutamine alone

Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.

Sponsors & Collaborators

  • Air Force Military Medical University, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031012 on ClinicalTrials.gov